A recent proof of principle study (carried out in colorectal cancer and melanoma pre-clinical models) has shown that loss of B2M, a genetic alteration that abrogates MHC class I expression and prevents CD8-mediated tumor recognition, can be overcome by a therapy designed to activated NK cells [47]. The gene discussed is B2M; the disease is neoplasm.